½ÃÀ庸°í¼­
»óǰÄÚµå
1305164

¼¼°èÀÇ Ã¼¾× äÃë ¹× Áø´Ü ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Global Body Fluid Collection And Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 254 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ü¾× äÃë ¹× Áø´Ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 334¾ï 1,000¸¸ ´Þ·¯¿¡¼­ 2030³â 696¾ï 6,000¸¸ ´Þ·¯¿¡ À°¹ÚÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â Á¶»ç ±â°£ µ¿¾È 9.62%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ü¾× äÃë ¹× Áø´ÜÀº Ç÷¾×, ¼Òº¯, Ÿ¾×, ³úô¼ö¾× µî ü³»ÀÇ ´Ù¾çÇÑ ¾×ü¸¦ äÃë, ºÐ¼® ¹× °Ë»çÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â °¨¿°, ¾Ï, ´ë»ç ÀÌ»ó, È£¸£¸ó ±ÕÇü Àå¾Ö µî ´Ù¾çÇÑ º´Àû »óŸ¦ Áø´ÜÇÏ°í ¸ð´ÏÅ͸µÇϱâ À§ÇØ ½Ç½ÃµË´Ï´Ù. ü¾× äÃë ¹× Áø´Ü¿¡´Â »ùÇà äÃë, ºÐ¼®À» À§ÇÑ »ùÇà Á¶Á¦, ´Ù¾çÇÑ Áø´Ü ±â¼úÀ» ÀÌ¿ëÇÑ »ùÇà ºÐ¼® µî ¿©·¯ ´Ü°è°¡ ÀÖ½À´Ï´Ù. ü¾× äÃë´Â Á¤¸Æ õÀÚ, ¼Òº¯ äÃë, Ÿ¾× äÃë µî ´Ù¾çÇÑ ¹æ¹ýÀ¸·Î ÀÌ·ç¾îÁú ¼ö ÀÖ½À´Ï´Ù. äÃëµÈ »ùÇÃÀº Çö¹Ì°æ °Ë»ç, ¹è¾ç, ºÐÀÚ Áø´Ü µî ´Ù¾çÇÑ Áø´Ü ¹æ¹ýÀ» »ç¿ëÇÏ¿© ½ÇÇè½Ç¿¡¼­ ó¸® ¹× ºÐ¼®µË´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç¸¦ ÅëÇØ ü³» ´Ü¹éÁú, È£¸£¸ó, È¿¼Ò µî ƯÁ¤ ¹°ÁúÀÇ Á¸Àç ¿©ºÎ¿Í ºñÁ¤»óÀûÀÎ ¼¼Æ÷³ª ¹Ì»ý¹°ÀÇ Á¸Àç¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ü¾× äÃë ¹× Áø´Ü °Ë»çÀÇ °á°ú´Â Áúº´À» Áø´ÜÇϰí, ¸ðµç Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϰí, Ä¡·á È¿°ú¸¦ Æò°¡ÇÏ´Â µ¥ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â Çö´ë ÀÇÇп¡¼­ ÇʼöÀûÀÎ ¿ä¼ÒÀ̸ç Áúº´ ¿¹¹æ°ú °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

Á¤±âÀûÀΠü¾× °Ë»ç°¡ ÇÊ¿äÇÑ ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ü¾× äÃë ¹× Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¾×ü »ý°Ë ¹× Â÷¼¼´ë ½ÃÄö½Ì°ú °°Àº ÷´Ü Áø´Ü ±â¼ú ¹× ±â¼úÀÇ °³¹ß·Î ü¾× äÃë ¹× Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ¿Í ÀÇ·áÁøÀÇ ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ´ú ħ½ÀÀûÀΠü¾× äÃë ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ßÀÌ Áß¿äÇÏ´Ù´Â ÀνÄÀÌ È®»êµÇ¸é¼­ ü¾× äÃë ¹× Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº Á¤ºÎ°¡ Áúº´ÀÇ Á¶±â ¹ß°ßÀ» ÃËÁøÇϰí ÀÇ·á ½Ã¼³À» °³¼±Çϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ½ÃÇàÇϰí ÀÖÀ¸¸ç, À̴ ü¾× äÃë ¹× Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í °¡»ó Áø·á°¡ È®»êµÇ¸é¼­ °³ÀÎÀÌ Áý¿¡¼­ ½±°Ô ü¾× äÃë ¹× Áø´Ü ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ü¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ü¾× äÃë ¹× Áø´Ü »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­:

ü¾× äÃë ¹× Áø´Ü ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼ÇÀº ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ Å¸°ÙÃþÀ» ½Äº°Çϰí ÇâÈÄ ºñÁö´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

»ùÇà À¯Çüº°

  • Ç÷¾×
  • Ÿ¾×
  • ¼Òº¯
  • ³úô¼ö¾×

Á¦Ç°º°

  • °Ë»ç/¼­ºñ½º
  • ŰƮ ¹× ¼Ò¸ðǰ
  • °Ë»ç Àåºñ

±â¼úº°

  • Â÷¼¼´ë ½ÃÄö½Ì(NGS)
  • ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)
  • FISH(Fluorescent In Situ Hybridization)
  • ±âŸ

¿ëµµº°

  • ¿¹ÈÄ ¿¹Ãø ¹× ½ºÅ©¸®´×
  • Áø´Ü ¹× ¸ð´ÏÅ͸µ
  • Ä¡·á °áÁ¤

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ã¼¾× äÃë ¹× Áø´Ü ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ü¾× äÃë ¹× Áø´Ü - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ü¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : »ùÇà À¯Çüº°

  • »ùÇà À¯Çüº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • °Ëü À¯Çüº° ºÐ¼®
  • Ç÷¾×
  • Ÿ¾×
  • ¼Òº¯
  • ³úô¼ö¾×

Á¦7Àå ü¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°º° ºÐ¼®
  • °Ë»ç/¼­ºñ½º
  • ŰƮ¡¤¼Ò¸ðǰ
  • ±â±¸

Á¦8Àå ü¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : ±â¼úº°

  • ±â¼úº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ±â¼úº° ºÐ¼®
  • Â÷¼¼´ë ½ÃÄý½Ì(NGS)
  • ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)
  • FISH(Fluorescent In Situ Hybridization)
  • ±âŸ

Á¦9Àå ü¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °³¿ä : ¿ëµµº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ¿ëµµº°
  • ¿¹ÈÄ Áø´Ü°ú ½ºÅ©¸®´×
  • Áø´Ü°ú ¸ð´ÏÅ͸µ
  • Ä¡·á ÀÇ»ç°áÁ¤

Á¦10Àå ü¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ü¾× äÃë ¹× Áø´Ü ±â¾÷ °æÀï »óȲ

  • ü¾× äÃë ¹× Áø´Ü ½ÃÀå °æÀï
  • ÆÄÆ®³Ê½Ê/Á¦ÈÞ/ÇÕÀÇ
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦12Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories
  • Illumina Inc
  • Guardant Health
  • QIAGEN
  • Johnson & Johnson
  • Laboratory Corporation of America Holdings
  • Biocept Inc
  • F. Hoffmann-La Roche Ltd.
  • MDxHealth SA.

*Âü°í : ±â¾÷ °³¿ä¿¡¼­ À繫 ³»¿ëÀ̳ª ÃÖ±ÙÀÇ µ¿ÇâÀº ÀÔ¼ö °¡´É ¿©ºÎ¿¡ µû¶ó ´Þ¶óÁö°Å³ª ºñ°ø°³ ±â¾÷ÀÇ °æ¿ì´Â Á¦°øµÇÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

ksm 23.08.22

The global demand for Body Fluid Collection And Diagnostics Market is presumed to reach the market size of nearly USD 69.66 BN by 2030 from USD 33.41 BN in 2022 with a CAGR of 9.62% under the study period 2023 - 2030.

Body fluid collection and diagnostics refer to the collection, analysis, and testing of various fluids within the body, such as blood, urine, saliva, and cerebrospinal fluid. These tests are performed to diagnose and monitor various medical conditions, including infectious diseases, cancer, metabolic disorders, and hormonal imbalances. Body fluid collection and diagnostics involve several steps, including the collection of the sample, preparation of the sample for analysis, and analysis of the sample using various diagnostic techniques. The collection of body fluids can be done through various methods, including venipuncture, urine collection, and saliva collection. Once the sample has been collected, it is processed and analyzed in a laboratory using a range of diagnostic methods, such as microscopy, culture, and molecular diagnostics. These tests can provide information related to the presence of specific substances in the body, such as proteins, hormones, and enzymes, as well as the presence of abnormal cells or microorganisms. The results of body fluid collection and diagnostics tests can be used to diagnose medical conditions, monitor the progression of any disease, and evaluate the effectiveness of treatments. These tests are an essential part of modern medical practice and play a vital role in disease prevention and management. 

Market Dynamics:

The increasing incidence of chronic diseases which require regular body fluid testing, is driving the demand for body fluid collection and diagnostics. The development of advanced diagnostic techniques and technologies, such as liquid biopsy and next-generation sequencing, has improved the accuracy and efficiency of body fluid collection and diagnostics. The adoption of minimally invasive procedures among patients and healthcare providers is driving the demand for less invasive body fluid collection methods. The awareness about the importance of early disease detection is scaling up, which is driving the demand for body fluid collection and diagnostics, as these tests can help detect diseases at an early stage when they are more treatable. Many governments are implementing initiatives to promote early disease detection and improve healthcare facilities, which is driving the growth of the body fluid collection and diagnostics market. Telemedicine and virtual consultations have become more prevalent, making it easier for individuals to access body fluid collection and diagnostic services from the comfort of their homes.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of body fluid collection and diagnostics. The growth and trends of body fluid collection and diagnostics industry provide a holistic approach to this study. 

Market Segmentation:

This section of the body fluid collection and diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Sample Type

  • Blood
  • Saliva
  • Urine
  • Cerebrospinal Fluid

By Product

  • Tests/Services
  • Kits & Consumables
  • Instruments

By Technology

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In Situ Hybridization (FISH)
  • Others

By Application

  • Prognostics & Screening
  • Diagnostics & Monitoring
  • Therapeutic Decision Making

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Body Fluid Collection And Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the body fluid collection and diagnostics market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Illumina Inc, Guardant Health, QIAGEN, Johnson & Johnson, Laboratory Corporation of America Holdings, Biocept Inc, F. Hoffmann-La Roche Ltd., MDxHealth SA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . BODY FLUID COLLECTION AND DIAGNOSTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Sample Type
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Technology
    • 3.7.4 Market Attractiveness Analysis By Application
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL BODY FLUID COLLECTION AND DIAGNOSTICS MARKET ANALYSIS BY SAMPLE TYPE

  • 6.1 Overview by Sample Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Sample Type
  • 6.4 Blood Historic and Forecast Sales by Regions
  • 6.5 Saliva Historic and Forecast Sales by Regions
  • 6.6 Urine Historic and Forecast Sales by Regions
  • 6.7 Cerebrospinal Fluid Historic and Forecast Sales by Regions

7 . GLOBAL BODY FLUID COLLECTION AND DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

  • 7.1 Overview by Product
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Product
  • 7.4 Tests/Services Historic and Forecast Sales by Regions
  • 7.5 Kits & Consumables Historic and Forecast Sales by Regions
  • 7.6 Instruments Historic and Forecast Sales by Regions

8 . GLOBAL BODY FLUID COLLECTION AND DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY

  • 8.1 Overview by Technology
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Technology
  • 8.4 Next Generation Sequencing (NGS) Historic and Forecast Sales by Regions
  • 8.5 Polymerase Chain Reaction (PCR) Historic and Forecast Sales by Regions
  • 8.6 Fluorescence In Situ Hybridization (FISH) Historic and Forecast Sales by Regions
  • 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL BODY FLUID COLLECTION AND DIAGNOSTICS MARKET ANALYSIS BY APPLICATION

  • 9.1 Overview by Application
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Application
  • 9.4 Prognostics & Screening Historic and Forecast Sales by Regions
  • 9.5 Diagnostics & Monitoring Historic and Forecast Sales by Regions
  • 9.6 Therapeutic Decision Making Historic and Forecast Sales by Regions

10 . GLOBAL BODY FLUID COLLECTION AND DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE BODY FLUID COLLECTION AND DIAGNOSTICS COMPANIES

  • 11.1. Body Fluid Collection And Diagnostics Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF BODY FLUID COLLECTION AND DIAGNOSTICS INDUSTRY

  • 12.1. Top Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Thermo Fisher Scientific Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Bio-Rad Laboratories
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Illumina Inc
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. Guardant Health
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. QIAGEN
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. Johnson & Johnson
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. Laboratory Corporation of America Holdings
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Biocept Inc
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments
  • 12.11. F. Hoffmann-La Roche Ltd.
    • 12.11.1. Company Overview
    • 12.11.2. Company Revenue
    • 12.11.3. Products
    • 12.11.4. Recent Developments
  • 12.12. MDxHealth SA.
    • 12.12.1. Company Overview
    • 12.12.2. Company Revenue
    • 12.12.3. Products
    • 12.12.4. Recent Developments

 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦